KZIA
What one share of Kazia Therapeutics Limited. holds
Pharmaceutical Preparations
The ongoing principal business of the Company has been pharmaceutical drug development. The Company is an emerging oncology-focused biotechnology company that has a portfolio of development candidates, diversified across several distinct technologies, with the potential to yield first-in-class and best-in-class agents in a range of oncology indications.
Kazia Therapeutics Limited.’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-06-30; the balance sheet is as of 2025-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$0.24 |
| Dividends | $0.00 |
| Cash and investments | $0.04 |
| Book value | −$0.07 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$1.15 | — | −$0.81 | — | $1.03 |
| 2021 | $0.96 | −$0.54 | — | −$0.58 | — | $2.14 |
| 2022 | $0.00 | −$1.37 | — | −$1.25 | — | $0.91 |
| 2023 | $0.00 | −$0.75 | — | −$0.55 | — | $0.35 |
| 2024 | $0.06 | −$0.67 | — | −$0.24 | — | −$0.20 |
| 2025 | $0.00 | −$0.24 | — | −$0.16 | — | −$0.07 |